Trial Profile
A Randomized, Open-label Phase III Non-inferiority Trial to Compare Indicators of Efficacy for MVA-BN Smallpox Vaccine to ACAM2000 in 18-40 Year Old Healthy Vaccinia-naive Subjects
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Smallpox vaccine (Primary) ; ACAM 2000
- Indications Smallpox
- Focus Pharmacodynamics; Registrational
- Sponsors Bavarian Nordic
- 20 Feb 2020 According to a Bavarian Nordic media release, in Jan 2020, the company completed the sale of the Priority Review Voucher, granted by the FDA in connection with the approval of JYNNEOS in 2019.
- 14 Nov 2019 Results published in the New England Journal of Medicine
- 14 Nov 2019 According to a Bavarian Nordic media release, results from this trial are published in The New England Journal of Medicine (NEJM).